Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy
Technology appraisal guidance from NICE
on 22 Jan 2025 NICE published evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours.
Recommendation
Anhydrous sodium thiosulfate is recommended, within its marketing authorisation, for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised, non-metastatic solid tumours. It is only recommended if the company provides it according to the commercial arrangement.
Why the committee made this recommendation
Babies, children and young people (1 month to 17 years) who have cisplatin chemotherapy for localised solid tumours can have hearing loss. There is no treatment to prevent this.
Clinical trial evidence shows that hearing loss is less likely in people having anhydrous sodium thiosulfate after cisplatin. If hearing loss develops, it is less severe in those who have had anhydrous sodium thiosulfate.
There are some uncertainties in the clinical evidence and in the economic model. But the cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, anhydrous sodium thiosulfate is recommended.
